Phase 2 N=27 Regorafenib in Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Number of Subjects Who Experience Grade 3-5 Toxicity as a Measure of Safety and Tolerability. — 20 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=156 Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis
Ulcerative Colitis
Primary: Change From Baseline in Adapted Mayo Score (MCS) at Week 12 — -1.94; -2.49; -1.50 score on a scale — p== 0.0091
Phase 2 N=12 Systemic Sclerosis (SSc) Vasculopathy: Improved Clinical Monitoring and Treatment
Rheumatologic Disease
Primary: Flow Mediated Dilatation (FMD)-Diameter of Artery — 3.79; 3.78 mm
Phase 2 N=72 Fatty Acid Supplementation in Children With ASD
Autism Spectrum Disorder
Primary: Bioavailability — 1.95; 1.80; 3.00; 0.80 mol%
Phase 2 N=124 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial
Neuroendocrine Carcinoma of the Lung and Thymus
Primary: Percentage of Participants Progression-free at 9 Months Based on Response Evaluation Criteria In Solid Tumors v1.1 (RECIST v1.1) — 0; 0; 0; 2.4 percentage of participants
Phase 2 N=28 A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome
Sjogren's Syndrome
Primary: Blood Cell Gene Expression — -0.0291486; 0.1330903; 0.2509076; 0.06726222 log 2 fold change — p=0.0000496
Phase 2 N=13 PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
Alzheimer Disease
Primary: Maximum Plasma Concentration (Cmax) — 1020; 1100 ng/mL
Phase 2 N=143 Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)
Relapsed or Refractory Multiple Myeloma
Primary: Objective Response Rate (RR) — 11.3 Percentage of Participants — p=0.419
Phase 2 N=57 Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation
Pulmonary Hypertension
Primary: Pulmonary Vascular Resistance (PVR) Ratio of Week 12 to Baseline — 0.585; 0.757 Ratio — p=0.0158
Phase 2 N=28 Essential Oils for Enhancing QOL in ASD
Autism Spectrum Disorder · Quality of Life · Sleep
Primary: Pediatric Quality of Life Inventory — 45.5; 56.2; 61.5; 65.3 Total Score
Phase 2 N=8 Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea
Morphea
Primary: Number of Participants Who Had a Reduction in Dermal Thickness of Sentinel Plaque — 5 Participants
Phase 2 N=166 A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies
Various Advanced Cancer
Primary: Number of Safety Lead-In Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0 Number of participants
Phase 2 N=18 Hyperbaric Treatment of Traumatic Brain Injury (TBI)
Traumatic Brain Injury
Primary: Number of Participants With Improved Cerebral Perfusion — 8 Participants
Phase 2 N=58 Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema
Hereditary Angioedema (HAE)
Primary: Proportion of Subjects With Improved or Stable Composite Visual Analog Scale (VAS) Score — 13.96; 15.04; 10.54; 18.42 VAS score - millimeters — p=0.0024
Phase 2 N=102 Optimal Vitamin D3 Supplementation Strategies for Acute Fracture Healing
Fracture
Primary: Fracture Healing Will be Assessed Clinically Using Function IndeX for Trauma (FIX-IT) — 10.1; 9.7; 9.3; 9.0 scores on a scale